Syros Pharmaceuticals Inc at ESMO Congress Conference Call Transcript
Thank you for standing by, and welcome to the Syros Pharmaceuticals Conference Call. (Operator Instructions) As a reminder, today's conference call may be recorded. I will now turn the conference to your host, Ms. Nancy Simonian. Please go ahead.
Great. Thank you for joining us today to review the SY-5609 Phase I dose escalation data and next steps. Dr. David Roth, our Chief Medical Officer; and Kristin Stephens, our Chief Development Officer, are also on the call, as is Dr. Eric Olson, our Chief Scientific Officer, who will be available for Q&A.
Next slide. Before we begin, I would like to remind everyone that statements we make on this conference call will include forward-looking statements. Any forward-looking statements made on this call represent our views only as of today. Actual events or results could differ materially as a result of various risks, uncertainties and other factors, including those risk factors
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |